Kevin Klemz compensation by year
Silk Road Medical Summary Compensation Table · all 2 fiscal years held| Component | FY2022 | FY2023 |
|---|---|---|
| Salary | $162,879 | $430,000 |
| Bonus | $100,000 | $0 |
| Stock awards | $999,990 | $2,970,296 |
| Option awards | $1,000,002 | $0 |
| Non-equity incentive | $105,221 | $222,139 |
| Pension and deferred compensation | $0 | $0 |
| All other | $8,415 | $13,200 |
| Total | $2,376,507 | $3,635,635 |
Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Silk Road Medical Inc DEF 14A filed April 26, 2024, accession 0001397702-24-000024, and prior-year filings.
How this page was built: the Silk Road Medical Inc filed document, accession 0001397702-24-000024. Every figure is read from that document and cited to the page and table it appears in. Filed April 26, 2024.
Equity holdings
unvested awards at FY2023 year-end| Type | Unvested units | Value at year-end | Exercise price |
|---|---|---|---|
| RSU | 86,076 | $1,056,153 | — |
| RSU | 20,011 | $245,535 | — |
| RSU | 15,244 | $187,044 | — |
| PSU | 2,120 | $26,012 | — |
| Option | 26,360 | — | $49.20 |
Per the Outstanding Equity Awards at Fiscal Year-End table in Silk Road Medical Inc's FY2023 proxy; value at the fiscal year-end close, as the company printed it.
Insider transactions since the last proxy
4 Form 4 lines since the FY2023 proxy (filed April 26, 2024)current to 2026-11-10 · updated nightly
| Date | Transaction | Plan | Shares | Price | Held after |
|---|---|---|---|---|---|
| 2024-09-17 | Grant or award | — | 29,062 | $0.00 | 29,062 |
| 2024-09-17 | Disposition to the issuer | — | 29,062 | — | 0 |
| 2024-09-17 | Disposition to the issuer | — | 162,926 | — | 0 |
| 2024-08-19 | Sale | — | 2,268 | $27.10 | 162,926 |
The 4 most recent of 4 lines, each as reported on the Form 4. "10b5-1" marks a trade the filing reports under a pre-arranged trading plan. View every Form 4 filing on EDGAR →
Silk Road Medical’s named executive officers, FY2023
as the company reported each| Named executive officer | Role | FY2023 total |
|---|---|---|
| Chas McKhann | Chief Executive Officer | $13,423,834 |
| Erica Rogers | Former President and Chief Executive Officer | $8,159,904 |
| Lucas Buchanan | Chief Operating Officer and Chief Financial Officer | $6,624,943 |
| Andrew Davis | Chief Commercial Officer | $4,866,640 |
| Kevin Klemz · this page | Executive Vice President, Chief Legal Officer and Secretary | $3,635,635 |
| Richard Ruedy | Executive Vice President of Regulatory and Clinical Affairs and Quality Assurance | $1,965,300 |
Kevin Klemz's compensation dossier, Silk Road Medical
You have read Kevin Klemz's totals and holdings. The dossier adds each equity grant Silk Road Medical disclosed for Kevin Klemz and Silk Road Medical's own disclosed peer group, where the company discloses them, with every row in a PDF and a CSV cited to its filing.
See an example →The full Silk Road Medical compensation record
free company briefThis page is one person within Silk Road Medical's record. The company brief lists every named executive, each linking to their own page.
Peer companies
named in the Silk Road Medical proxy · each links to its own free briefCompensation, the day it’s disclosed
The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.
How this record is built
Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are Silk Road Medical's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.